BioMaxima S.A. Logo

BioMaxima S.A.

Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.

BMX | WAR

Overview

Corporate Details

ISIN(s):
PLBIOMX00015
LEI:
2594007GAALFMXP4YB89
Country:
Poland
Address:
Lublin Vetterów 5, 20-277 Lublin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioMaxima S.A. is a manufacturer in the biotechnology sector specializing in the in vitro diagnostics (IVD) market. The company develops and produces a comprehensive range of solutions for laboratory diagnostics, supporting medical professionals and diagnosticians. Its portfolio encompasses microbiological media, reagents, specialized equipment, and IVD tests. Key application areas include clinical chemistry, haematology, and the diagnosis of infectious diseases, featuring systems for determining drug sensitivity and reference strains for microorganisms.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 14:50
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 815 bytes
2025-11-21 14:12
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 951 bytes
2025-09-30 17:15
Audit Report / Information
Raport Biegłego z przeglądu skróconego spawozdania jednostkowego
Polish 345.0 KB
2025-09-30 17:15
Audit Report / Information
Raport Biegłego z przeglądu sprawozdania skonsolidowanego
Polish 348.4 KB
2025-09-30 17:15
Management Discussion and Analysis
Sprawozdanie Zarządu za I półrocze 2025
Polish 727.0 KB
2025-09-30 17:15
Interim Report
Skonsolidowane sprawozdanie półroczne ze skróconymsprawozdaniem finansowym
Polish 1.5 MB
2025-09-30 17:15
Interim Report
List Prezesa Zarządu do akcjonariuszy
Polish 255.8 KB
2025-09-26 08:18
Regulatory News Service
Dostawa analizatora - Content (PL)
Polish 663 bytes
2025-08-27 12:45
Regulatory News Service
Informacja o otrzymaniu dofinansowania w kwocie 1.097.835,17 zł na rozbudowę of…
Polish 1.7 KB
2025-08-08 20:29
Director's Dealing
Zawiadomienie 19 MAR
Polish 8.0 KB
2025-08-08 20:29
Report Publication Announcement
Zawiadomienie od osoby zobowiązanej - Content (PL)
Polish 213 bytes
2025-07-15 12:07
Business and Financial Review
Podpisanie znaczącej umowy - Content (PL)
Polish 581 bytes
2025-06-27 14:00
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 776 bytes
2025-06-25 13:05
Major Shareholding Notification
zal01_Wykaz_akcjonariuszy.pdf
Polish 127.8 KB
2025-06-25 13:05
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów podczas WZ w dniu 25.6.…
Polish 242 bytes

Automate Your Workflow. Get a real-time feed of all BioMaxima S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioMaxima S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioMaxima S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.